Sputnik V is marketed overseas by Russia’s sovereign wealth fund, called the Russian Direct Investment Fund (RDIF). RDIF said Reuters’ reporting contained “false and inaccurate statements” based on anonymous sources who are attempting to harm Sputnik V as part of a disinformation campaign. The Slovakian government this month said it sold most of its Sputnik V back to Russia, citing low interest. Anvisa publicly said there was a risk the adenovirus in Sputnik V could replicate, potentially causing a negative reaction in recipients. RDIF, in its responses to Reuters, said Gamaleya “has confirmed that no replication-competent adenoviruses (RCA) were ever found in any of the Sputnik V vaccine batches that have been produced.”

Source: bd News24 July 13, 2021 06:22 UTC